Health Canada approved the first generic version of Novo Nordisk’s Ozempic, clearing Dr. Reddy’s Laboratories’ semaglutide injection submission. The decision follows a review that Health Canada said found the product meets safety, efficacy, and quality standards and is pharmaceutically equivalent to the brand. The generic is indicated for once-weekly treatment of adult patients with type 2 diabetes to manage blood sugar levels. Health Canada said it expects generic availability to improve access through potential cost savings and will continue monitoring the safety and effectiveness of semaglutide generics. The approval is likely to accelerate payer and prescriber discussions as Canada moves toward broader semaglutide price competition.